Kalshi launches betting markets for FDA approvals and pharma trials
Prediction market Kalshi now allows wagers on late-stage drug trials and FDA approvals, raising concerns about insider trading and the integrity of clinical data that investors rely on.
Kalshi launched a suite of prediction markets on Thursday allowing users to wager on Phase 3 clinical trial outcomes and full FDA drug approvals. The platform partnered with clinical trial monitor AppliedXL to offer bets on more than a dozen pharmaceutical outcomes. Trading volume reached $128,401 by Thursday afternoon.
The market is currently restricted to late-stage trials run by established biopharma companies with market capitalizations exceeding $500 million. Active contracts include whether the FDA will approve Gilead Sciences' experimental cancer drug anito-cel by year-end and if AriBio's Alzheimer's treatment will meet its Phase 3 goals. Bettors can also wager on the timing of Eli Lilly's weight loss drug retatrutide approval, while 56% of participants bet that a cure for Type 1 diabetes will not be approved before 2033.
Kalshi argues these markets provide a new layer of price discovery for the pharmaceutical sector. The company says experts and investors can collectively translate private information into a single, public probability. As Reuters summarized the initiative, it makes "drug-development odds public for the first time."
However, researchers and bioethicists warn the financial incentives could undermine the very data these markets aim to predict. Critics told Stat News that the potential for profit might encourage individuals with influence over a study to alter or delay decisions. They warned the focus could shift from discovering accurate medical evidence toward influencing market outcomes.
While Kalshi requires employment verification and attempts to restrict access for those with insider information, enforcement remains a concern. Privileged individuals—such as clinical investigators, doctors, nurses, or company employees—could exploit nonpublic data before results are announced. For investors, the danger is that even if regulators later detect insider trading, the underlying clinical trial may already be compromised.
The existence of these markets could also introduce unpredictable variables into drug development timelines. Patients might decide to withdraw from or remain in a study based on betting odds rather than medical advice. Such fluctuations in trial participation could ultimately delay regulatory decisions and disrupt pharmaceutical revenue models.
